Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting Oct 27, 2007
73 BOSTON, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced results from an analysis of VYVANSE(TM) (lisdexamfetamine dimesylate) effect size. These findings were presented today at a national meeting of psychiatrists in Boston. (PR Newswire)
VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment Oct 26, 2007
BOSTON October 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE (lisdexamfetamine dimesylate), the first prodrug stimulant. Findings from this phase III pivotal trial were presented today at a national... (EurekAlert!)
LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon Oct 18, 2007
Philadelphia, PA October 17, 2007 According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery system where the majority of the drugs active ingredient, 5-aminosalicyclic acid (5-ASA), is released over a prolonged period in the simulated colon. The colon is the site of inflammation in ulcerative colitis. (EurekAlert!)
Shire Divests Non-Core Product Portfolio to Almirall Oct 8, 2007
Reinforcing Strategic Focus on Growth-Driving Global Products BASINGSTOKE, England, October 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces that it has agreed to sell a portfolio of non core products to Almirall for a cash consideration of $213m. The portfolio includes the dermatology products, SOLARAZE(R) (3% gel diclofenac sodium) and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted products1... (PR Newswire)
FTSE 100 Declines: Northern Rock, Alliance & Leicester Lead the Retreat Sep 15, 2007
Shire Plc (SHP LN) declined 92 pence, or 7. 4 percent, to 1,154. (Bloomberg -- UK)
Addressing inmates' medical needs Aug 14, 2007
Brackett said the county has alerted medical care provider Southern Health Partners (SHP) that it is terminating its contract at the end of the month ... SHP is a primary provider for medical care for several county-operated jail in the South ... A primary reason, according to Brackett, is SHP's inability to provide inmates access to mental health services, as is required by North Carolina state law, including substance abuse treatment and counseling. (Lenoir News Topic, NC)
Shire's new ADHD medication, VYVANSE TM (lisdexamfetamine dimesylate) now available in US Jul 28, 2007
Philadelphia, PA July 27, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that VYVANSE TM(lisdexamfetamine dimesylate), a new once-daily medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD), is now available in U.S. pharmacies nationwide. In a clinical study, VYVANSE provided consistent ADHD symptom control throughout the day based upon parent reports in the morning (approximately 10am), afternoon (approximately 2pm), and early... (EurekAlert! -- Business News)
Shire announces filing of VYVANSE for treatment of ADHD in adults Jun 30, 2007
Philadelphia, PA June 29, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VYVANSE (lisdexamfetamine dimesylate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. This application is subject to a 10-month FDA review period. (EurekAlert! -- Business News)
Shire Demonstrates Commitment to Improving Patient Adherence in End Stage Renal Disease as New Phosphate-Binder FOSRENOL(R) Launches in Europe Jun 25, 2007
QUICK SEARCH BY ORGANIZATION. FREE SUBSCRIPTION SERVICES. (Canada Newswire)
Notre Dame Baseball Draft Recap And Updated Player Bios Jun 23, 2007
his impressive 2007 season at Seton Hall Prep - the nation's No. 1-ranked team - included an 11-0 record (setting the SHP record for wins in a season), 0 ... helped SHP win its third straight state title (10-1 over St. Joseph's) ... one of four players on the 2007 SHP team who signed with Division I programs (Porcello with North Carolina, Brooks with Wake Forest and rightfielder Nick Natale with Rice). (Und.com)
Shire Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD Jun 21, 2007
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist, which has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Unlike some other... (PR Newswire)
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo Jun 20, 2007
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 20 /PRNewswire-FirstCall/ -- - Novel Biopharmaceutical Drug Candidate for the Prevention and Reduction of Scarring in Connection With Both Therapeutic and Cosmetic Surgery - a Market Served by Specialist Physicians - In-License Includes Exclusive Worldwide Rights Except for EU member States - Financial Payments Geared to Success and Linked to Significant Milestones - Renovo Estimates a Potential New Multi-Billion Market Opportunity in the... (PR Newswire)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Jun 14, 2007
As part of the rebalancing, the following changes represent the additions and deletions to the Indexes: -- HealthShares(TM) Cancer Index added Shire PLC (ADR) (Nasdaq GS: SHPGY); and dropped Telik Inc. (Nasdaq GM: TELK). -- HealthShares(TM) Emerging Cancer Index added Telik Inc. (Nasdaq GM: TELK); and dropped Shire PLC (ADR) (Nasdaq GS: SHPGY) ... -- HealthShares(TM) European Drugs Index added Novo Nordisk A/S - B Shares (Copenhagen: NOVOB), KRKA (Ljubljana: KRKG), Grifols SA (Continuous: GRF);... (PR Newswire)
Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD May 24, 2007
SAN DIEGO May 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced that VYVANSE (lisdexamfetamine dimesylate) effectively controlled Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase III open-label extension trial results. (EurekAlert!)
12-month study demonstrated tolerability and efficacy of Daytrana May 24, 2007
SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego. "We... (EurekAlert!)
Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms May 24, 2007
San Diego, US May 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly... (EurekAlert!)
Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW May 23, 2007
Washington, D.C. May 22, 2007 A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007 showed Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) LIALDA (mesalamine) is well tolerated in mild to moderate UC patients. Today, secondary endpoints of study 303 were presented as post-hoc analyses at Digestive Disease Week (DDW). (EurekAlert!)
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults May 20, 2007
BASINGSTOKE, United Kingdom, and PHILADELPHIA, May 19 /PRNewswire/ -- Shire plc (LSE: SHP; Nasdaq: SHPGY; TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for SPD465 (triple-bead mixed amphetamine salts [MAS], an investigational oral stimulant intended to provide symptom control of ADHD in adults for up to 16 hours with one daily dose. Following receipt of this approvable letter, Shire is evaluating its options related to... (PR Newswire)
DEA schedules VYVANSE, clearing way for launch of first prodrug stimulant ADHD treatment May 4, 2007
Basingstoke, U.K., Philadelphia, PA May 3, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Drug Enforcement Administration (DEA) has classified VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), as a Schedule II controlled substance, following the earlier recommendation of the U.S. Food and Drug Administration (FDA). The DEA schedule classification of VYVANSE represents the final step in the Federal government's administrative approval process... (EurekAlert! -- Business News)
Shire Plc Announces Refinancing of Bank Facilities Connected With the Recent Acquisition of New River Through the Launch of US$1,000 Million Convertible Bonds due 2014 to be Offered Outside the United States and to Non-US Persons Only May 2, 2007
This Announcement is not for Distribution or Release in Jersey, Canada and Japan or in any Other Jurisdiction in Which Offers or Sales Would be Prohibited by Applicable Law BASINGSTOKE, England, May 2 /PRNewswire-FirstCall/ -- Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it intends to make an offering of US$1,000 million principal amount of Convertible Bonds ("Bonds") due 2014 to international institutional investors outside the United States that are... (PR Newswire)
HealthShares(TM) Announces Change to the HealthShares(TM) European Drug Index Apr 14, 2007
NEW YORK, April 13 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard s, the calculating agent for the HealthShares(TM) European Drug Index, that effective at the opening of trading on Wednesday April 18, 2007, Solvay SA (SOLB-Brussels) and Shire PLC (SHP- London) will replace Actavis Group (ACT-Iceland) and AES Chemunex SA (AESCH- France) in the HealthShares(TM) European Drug Index.... (PR Newswire)
Steps for women's health Apr 6, 2007
But it was cheering to read that UHS now offers the new human papillomavirus (HPV) vaccine, Gardasil, and that the Student Health Plan (SHP) will cover 80 percent of the a fairly expensive course of three shots over six months ... It should try to find a way to cover the vaccine's entire cost for SHP subscribers and subsidize the vaccine even for women with private health insurance so that they too can be protected. (The Daily Princetonian, NJ)
FDA approval of Vyvanse as a novel treatment for ADHD Feb 25, 2007
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). more. (SpiritIndia)
Neglected housing Feb 18, 2007
-based SHP Management, which bought the complex in 2002, said the inspection "is a snapshot of current property conditions" and that the company has made a number of improvements. Items identified as critical to the health and safety of residents were immediately corrected, Frost said. (The Clarion-Ledger)
FDA approves LIALDA (mesalamine) Jan 19, 2007
Basingstoke, UK and Philadelphia, US January 16, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDATM(mesalamine) with MMX technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine. (EurekAlert! -- Business News)
India acquires first US-built warship Jan 18, 2007
Thursday, January 18, 2007. Indo-Asian News Service. (Hindustan Times, India)
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission Jan 11, 2007
BASINGSTOKE, England and CAMBRIDGE, Massachusetts, January 11 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces today that the European Commission has granted a marketing authorisation for the use of ELAPRASE(R) (idursulfase) for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II or MPS II)(1). ELAPRASE is the first and only enzyme replacement therapy for people suffering from Hunter syndrome and it was launched in the U.S. in July... (PR Newswire)
Series of lectures could aid retirees Dec 31, 2006
Jim Concotelli, director of Wellness and Resident Life for SHP Senior Living Services, LLC, will talk about living wise and well. Jan. 24 at 2 p.m. -- "What Can You Expect in 2007?" -- Deborah Musbach and Jack Musbach II, both of Merrill Lynch, will talk about the opportunities and challenges that one can expect for their investments in 2007. (Orlando Sentinel -- News)
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD Dec 22, 2006
Dec. 21 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (Nasdaq: ) and its collaborative partner Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has issued a second approvable letter for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ... SOURCE Shire plc (SHP); New River Pharmaceuticals (NRPH). (PR Newswire)
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy Nov 20, 2006
Shire Shire (LSE: SHP) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI), renal diseases and human genetic therapies. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the... (Canada Newswire)
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17 Nov 17, 2006
- Data Presented at U.S. Psychiatric l Health Congress - NEW ORLEANS, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (Nasdaq: SHPGY), (LSE: SHP), (TSX: SHQ) announced today that once-daily doses of the investigational medication guanfacine extended release (GXR, also referred to as SPD503), a selective alpha-2A-adrenoceptor agonist, significantly improved symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years when used as a monotherapy. The phase III trial... (PR Newswire)
Shire bioequivalence study results of SPD465, investigational drug for adults with ADHD Nov 17, 2006
New Orleans November 16, 2006 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that a single once-daily morning dose of the investigational amphetamine compound SPD465, extended release triple-bead mixed amphetamine salts, designed to reduce symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults for up to 16 hours, was bioequivalent to a dose of ADDERALL XR (mixed salts of a single-entity amphetamine product) followed by a dose of mixed amphetamine salts... (EurekAlert!)
Shire analysis compares stimulant to nonstimulant ADHD medications in patients aged 8 to 15 years Nov 17, 2006
New Orleans November 16, 2006 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced the results of a study which suggested that stimulant medications such as ADDERALL XR (mixed salts of a single-entity amphetamine product) are significantly more effective than non-stimulant medications in the treatment of patients aged 8 to 15 with Attention-Deficit/Hyperactivity Disorder (ADHD). The study, a meta-analysis of 29 double-blind, placebo-controlled treatment studies undertaken over the past... (EurekAlert!)
Benchmark Stocks Fall for a Second Day; WPP, AstraZeneca Lead the Decline Oct 28, 2006
Shire Plc (SHP LN) advanced 21 pence, or 2. 2 percent, to 967. (Bloomberg -- UK)
Lisdexamfetamine dimesylate in ADHD phase 3 data presented Oct 28, 2006
SAN DIEGO October 30, 2006 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III... (EurekAlert!)
Many adults with psychiatric disorders may also have undiagnosed ADHD Oct 28, 2006
San Diego, CA October 27, 2006 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that many adults with a depressive disorder, Bipolar Disorder (BPD), or an anxiety disorder may also have undiagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), according to a longitudinal retrospective medical claims analysis presented today at a major medical meeting of child and adolescent psychiatrists. According to an analysis of medical claims derived from a large managed care database in... (EurekAlert!)
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management Oct 27, 2006
Shorter Wear Time Provides Shorter Duration of Effect, Offering Individualized ADHD Symptom Management SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA(TM) (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability... (PR Newswire)
FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD Oct 7, 2006
BASINGSTOKE, England and PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today that its collaborative partner New River Pharmaceuticals Inc. (Nasdaq: ) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD). This result is generally consistent with historical responses from FDA following their... (PR Newswire)
New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104 Oct 7, 2006
In January 2005, New River and Shire plc (LSE: SHP), (Nasdaq: ), (TSX: SHQ) signed a collaboration agreement to develop and commercialize NRP104. According to the FDA's letter, marketing approval of NRP104 is contingent upon final scheduling by the U.S. Drug Enforcement Administration (DEA). (PR Newswire)
New Treatment a Success for Anaemia Associated With Chronic Kidney Disease Sep 14, 2006
For further information on Shire (LSE: SHP), please visit the Company's website. . (Canada Newswire)
Shire and Barr Settle All Pending Litigation Concerning ADDERALL XR(R) and enter into Development and License Agreement Aug 15, 2006
BASINGSTOKE, England and PHILADELPHIA, Aug. 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announces that it has settled all pending litigation with Barr Laboratories, Inc. ("Barr"), a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: ) in connection with Barr's Abbreviated New Drug Application ("ANDA") and its attempt to market generic versions of Shire's ADDERALL XR (extended-release mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity... (PR Newswire)
Abuse liability study results of lisdexamfetamine dimesylate (NRP104) presented at CPDD Jul 1, 2006
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that results of three abuse liability studies with lisdexamfetamine dimesylate (NRP104), an investigational drug for the treatment of ADHD, were presented last week at the 68th annual meeting of the College on Problems of Drug Dependence (CPDD) in Scottsdale, AZ. Principal investigator Donald Jasinski, Professor of Medicine, Chief Center for Chemical Dependence, Johns Hopkins Bayview Medical Center, presented these results. New River... (EurekAlert!)
Shire's DAYTRANA, first patch medication for ADHD in children, now available in pharmacies Jul 1, 2006
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced the availability of DAYTRANA (methylphenidate transdermal system), the first and only transdermal medication approved to treat the symptoms of ADHD. The ADHD patch DAYTRANA, a once daily transdermal formulation of methylphenidate, is now available in retail pharmacies in 10 mg, 15 mg, 20 mg and 30 mg dosage strengths and is offered in trade packages of 10 patches for titration and 30 patches for ongoing therapy. The FDA approved DAYTRANA on... (EurekAlert!)
Summer Sales in Full Swing Jun 27, 2006
Use coupon code SHP at checkout to get free shipping on orders of $100 or more. Coupon expires July 13. (SmartMoney)
BAE, EMI, Cadbury, C&C, Persimmon, Vendanta: U.K., Irish Equity Preview Jun 26, 2006
Shire Plc (SHP LN): The U.K.'s third-largest drugmaker may receive a bid from Swiss biotechnology Serono SA, according to the Independent newspaper. Shire may receive U.S. approval for its enzyme replacement therapy drug in the coming weeks, the Independent said. (Bloomberg -- UK)
New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 Study Jun 19, 2006
Under review by the U.S. Food and Drug Administration as a potential treatment for pediatric ADHD, NRP104 is the subject of a collaboration agreement between New River and Shire plc (LSE: SHP; Nasdaq: SHPGY; TSX: SHQ). New River and Dr. Jasinski plan to webcast a conference call on Monday, June 26 at 3:00 p.m. EDT to elaborate upon the studies and their results. (PR Newswire)
Innovative Technology for Treatment of Renal Anaemia Unveiled Today Jun 16, 2006
Shire (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), focuses its business on central nervous system, gastrointestinal, general products with an emphasis on renal, and human genetic therapies - all being areas in which Shire has a commercial presence. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. (Canada Newswire)
DAYTRANA (methylphenidate transdermal system) significant reduces ADHD symptoms May 25, 2006
Philadelphia, US Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its methylphenidate transdermal system (MTS), DAYTRANA TM demonstrated statistically significant reductions in the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) and was generally well tolerated in patients aged 6 to 12 years in four analyses of two clinical trials reported at a major medical meeting in Toronto. "Children with ADHD and their caregivers must manage symptom control throughout the day in a... (EurekAlert!)
NRP104 significantly reduced symptoms of attention deficit hyperactivity disorder in children May 25, 2006
TorontoV Shire plc (Nasdaq: SHPGY, LSE: SHP, TSX: SHQ) and New River Pharmaceuticals Inc. (Nasdaq: NRPH) announced today that treatment with the investigational drug, lisdexamfetamine dimesylate (NRP104), demonstrated statistically significant reduction in the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years according to the results of a phase III trial presented today at the American Psychiatric Association (APA) annual meeting. A phase II trial of... (EurekAlert!)
Shire's DAYTRANATM transdermal patch approved by FDA for treatment of ADHD Apr 8, 2006
Philadelphia, PA, US and Basingstoke, UK -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) approved DAYTRANA (methylphenidate transdermal system), the first and only non-oral medication for the treatment of attention deficit hyperactivity disorder (ADHD). DAYTRANA, a once daily transdermal patch formulation of methylphenidate, will be available in 10 mg, 15 mg, 20 mg and 30 mg dosage strengths. (EurekAlert! -- Business News)
Shire's DAYTRANA(TM) Transdermal Patch Approved by FDA for Treatment of ADHD Apr 7, 2006
PHILADELPHIA, Pennsylvania and BASINGSTOKE, England, April 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) approved DAYTRANA (methylphenidate transdermal system), the first and only non-oral medication for the treatment of attention deficit hyperactivity disorder (ADHD). DAYTRANA, a once daily transdermal patch formulation of methylphenidate, will be available in 10 mg, 15 mg, 20 mg and 30 mg dosage... (PR Newswire)
Shire plc: ADDERALL XR(R) - The Court Sets October 30, 2006 Bench Trial Mar 11, 2006
PHILADELPHIA, Pennsylvania and BASINGSTOKE, England, March 10 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that in the pending New York litigation between Shire and Barr Laboratories, Inc. involving alleged infringement of U.S. Patent Nos. 6,322,819 and 6,605,300, the Court in a pre-trial conference scheduled the bench trial to commence on October 30, 2006. (PR Newswire)
Shire plc - Statement Regarding the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting Feb 10, 2006
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, February 10 /PRNewswire-FirstCall/ -- As the leader in ADHD treatment, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), is supportive of the goals of yesterday's meeting of the US FDA Drug Safety and Risk Management Advisory Committee. However, we feel it is important to put several of the issues into perspective. (PR Newswire)
NICE (National Institute for Health and Clinical Excellence) Review of Treatments for Alzheimer's Disease Jan 23, 2006
BASINGSTOKE, England, January 23 /PRNewswire-FirstCall/ -- Shire welcomes the NICE announcement that Alzheimer's disease (AD) drugs should remain available on the NHS for patients already prescribed treatment and for new patients diagnosed with moderate AD. Shire will work with other stakeholders to make the case that patients with mild AD should also continue to have access to these drugs on the NHS. Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) "Shire is encouraged that the new NICE appraisal... (PR Newswire)
